A new paper published today in the prestigious journal Science Translational Medicine describes the discovery and biological profiling of an exciting new anti-malarial clinical drug candidate, MMV390048, effective against resistant strains of the malaria parasite, and across the entire parasite lifecycle, with the potential to cure and protect in a single dose. The research was conducted by the University of Cape Town (UCT)'s Drug Discovery and Development Centre, H3D, and Medicines for Malaria Venture (MMV), in collaboration with a team of international researchers.
The scientist poised to save millions from the devastation of malaria
Africa has been at the mercy of Malaria for thousands of years. Killing half a million people on the continent each year, the disease is yet to meet its equal. But this could soon change. A team of young scientists at UCT has uncovered a compound that has the potential to attack Malaria at all three stages of its cycle through the human body, with a force beyond anything in modern medicine.
Professor Dame Sally Davies, the Chief Medical Officer for England and UK government adviser, has appointed an expert advisory board to support the Global Antimicrobial Resistance Innovation Fund (GAMRIF).
The 12 member board will advise how the UK can best spend an additional £50 million over the next 5 years to work with global partners to fund innovative initiatives to tackle drug resistant infections, which includes resistance to antibiotics.
The UK government has appointed an expert advisory board to advise how it can best spend an additional 50 million British pounds over the next five years to fund innovative initiatives to tackle drug resistant infections, which include resistance to antibiotics.
Professor Kelly Chibale, founder and director of the University of Cape Town’s Drug Discovery and Development Centre (H3D) and founding director of the South African Medical Research Council/UCT drug discovery and development research unit, has been selected as a member of the advisory board.